SG190952A1 - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents
Compositions and methods for treating amyloid plaque associated symptoms Download PDFInfo
- Publication number
- SG190952A1 SG190952A1 SG2013042288A SG2013042288A SG190952A1 SG 190952 A1 SG190952 A1 SG 190952A1 SG 2013042288 A SG2013042288 A SG 2013042288A SG 2013042288 A SG2013042288 A SG 2013042288A SG 190952 A1 SG190952 A1 SG 190952A1
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- compositions
- associated symptoms
- amyloid plaque
- plaque associated
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41906010P | 2010-12-02 | 2010-12-02 | |
| US201161548542P | 2011-10-18 | 2011-10-18 | |
| PCT/US2011/063121 WO2012075422A2 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG190952A1 true SG190952A1 (en) | 2013-07-31 |
Family
ID=46172597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013042288A SG190952A1 (en) | 2010-12-02 | 2011-12-02 | Compositions and methods for treating amyloid plaque associated symptoms |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20140037638A1 (enExample) |
| EP (1) | EP2646053A4 (enExample) |
| JP (1) | JP2014502276A (enExample) |
| KR (1) | KR20140017513A (enExample) |
| CN (1) | CN103338786A (enExample) |
| AU (1) | AU2011336360A1 (enExample) |
| BR (1) | BR112013013723A2 (enExample) |
| CA (1) | CA2819679A1 (enExample) |
| MX (1) | MX2013006116A (enExample) |
| NZ (1) | NZ611614A (enExample) |
| RU (1) | RU2013130002A (enExample) |
| SG (1) | SG190952A1 (enExample) |
| WO (1) | WO2012075422A2 (enExample) |
| ZA (1) | ZA201303996B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| BR112017006419A2 (pt) | 2014-09-30 | 2017-12-19 | Univ Washington | medições cinéticas de tau |
| EP3452074A4 (en) * | 2016-05-03 | 2019-12-11 | University of South Florida | COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN |
| US11124562B2 (en) | 2016-10-28 | 2021-09-21 | Washington University | Anti-ApoE antibodies |
| CA3070100A1 (en) * | 2017-07-17 | 2019-01-24 | Janssen Biotech, Inc. | Antigen binding regions against fibronectin type iii domains and methods of using the same |
| CN120098122A (zh) * | 2019-05-28 | 2025-06-06 | 总医院公司 | Apoe抗体、融合蛋白及其用途 |
| WO2023069892A1 (en) * | 2021-10-19 | 2023-04-27 | Short Jay M | Conditionally active proteins for neurodegenerative diseases |
| AU2023399623A1 (en) * | 2022-11-30 | 2025-07-03 | Bio-Techne Corporation | Natural killer cell engagers |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI951701L (fi) * | 1992-10-13 | 1995-04-10 | Univ Duke | Menetelmät Alzheimerin taudin tunnistamiseksi |
| AR047729A1 (es) * | 2003-11-28 | 2006-02-15 | Astrazeneca Ab | Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) |
| AU2005228764A1 (en) * | 2004-03-30 | 2005-10-13 | Renomedix Institute Inc. | Remedy for prion disease and method of producing the same |
| EP1991252A2 (en) * | 2006-02-21 | 2008-11-19 | Oklahoma Medical Research Foundation | Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| AU2007332473B2 (en) * | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| US9102717B2 (en) * | 2010-03-01 | 2015-08-11 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
-
2011
- 2011-12-02 RU RU2013130002/10A patent/RU2013130002A/ru not_active Application Discontinuation
- 2011-12-02 NZ NZ611614A patent/NZ611614A/en not_active IP Right Cessation
- 2011-12-02 CA CA2819679A patent/CA2819679A1/en not_active Abandoned
- 2011-12-02 MX MX2013006116A patent/MX2013006116A/es not_active Application Discontinuation
- 2011-12-02 US US13/990,777 patent/US20140037638A1/en not_active Abandoned
- 2011-12-02 BR BR112013013723A patent/BR112013013723A2/pt not_active IP Right Cessation
- 2011-12-02 JP JP2013542218A patent/JP2014502276A/ja active Pending
- 2011-12-02 WO PCT/US2011/063121 patent/WO2012075422A2/en not_active Ceased
- 2011-12-02 AU AU2011336360A patent/AU2011336360A1/en not_active Abandoned
- 2011-12-02 EP EP11844128.6A patent/EP2646053A4/en not_active Withdrawn
- 2011-12-02 SG SG2013042288A patent/SG190952A1/en unknown
- 2011-12-02 CN CN2011800667946A patent/CN103338786A/zh active Pending
- 2011-12-02 KR KR1020137016719A patent/KR20140017513A/ko not_active Withdrawn
-
2013
- 2013-05-31 ZA ZA2013/03996A patent/ZA201303996B/en unknown
-
2016
- 2016-08-22 US US15/243,495 patent/US20160355581A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160355581A1 (en) | 2016-12-08 |
| US20140037638A1 (en) | 2014-02-06 |
| CN103338786A (zh) | 2013-10-02 |
| WO2012075422A2 (en) | 2012-06-07 |
| JP2014502276A (ja) | 2014-01-30 |
| WO2012075422A3 (en) | 2012-10-04 |
| ZA201303996B (en) | 2015-10-28 |
| EP2646053A4 (en) | 2014-05-28 |
| NZ611614A (en) | 2015-07-31 |
| KR20140017513A (ko) | 2014-02-11 |
| EP2646053A2 (en) | 2013-10-09 |
| CA2819679A1 (en) | 2012-06-07 |
| MX2013006116A (es) | 2013-10-17 |
| BR112013013723A2 (pt) | 2019-09-24 |
| RU2013130002A (ru) | 2015-01-10 |
| AU2011336360A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG190952A1 (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| UA109123C2 (uk) | Пробіотична композиція для застосування в лікуванні запалення кишечнику | |
| UA107600C2 (uk) | АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ | |
| MX364200B (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
| CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
| MY163275A (en) | Ibat inhibitors for the treatment of liver diseases | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201590247A1 (ru) | Антитела к siglec-15 | |
| MX2011009690A (es) | Métodos y composiciones para trastornos relacionados con la proliferación celurar. | |
| NI201200171A (es) | Anticuerpos hacia gdf8 humano | |
| CO6571886A2 (es) | Antagonistas de pcsk9 | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| EA201291336A1 (ru) | Замещенные 5-фтор-1н-пиразолопиридины и их применение | |
| BR112012026112A2 (pt) | método de tratar obesidade usando moduladores de inflamação antioxidantes | |
| MX343640B (es) | Promotor de osteogenesis. | |
| PH12012501680A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| PT2621520E (pt) | Composições de colagenase g e colagenase h para o tratamento de doenças que envolvem alterações de colagénio | |
| GB201109238D0 (en) | Antibodies | |
| JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
| TN2015000277A1 (en) | Bmp-6 antibodies | |
| MX2014006337A (es) | Composiciones de proteina del gen 3 de bacteriofago y sus usos como agentes de union amiloides. | |
| EA201200428A1 (ru) | Композиция и способ для лечения ожирения |